There is a lack of definitive data on the effective management of acute respiratory distress
syndrome (ARDS) in infants and children. The development and validation of the Berlin …

The treatment of neonatal respiratory distress syndrome with surfactant represents a
successful culmination of decades of basic and clinical research. In many babies, respiratory …

Surfactant for respiratory distress syndrome: are there impo... : Current Opinion in Pediatrics
Surfactant for respiratory distress syndrome: are there important clinical differences among …

Regardless of the cause, a common pathophysiological feature of patients with acute
respiratory distress syndrome is a dysfunction of the endogenous surfactant system …

Exogenous surfactant therapy is widely used in the management of neonatal respiratory
distress syndrome. Two types of surfactants are available: synthetic surfactants, and those …

This article reviews exogenous surfactant therapy and its use in mitigating acute lung injury
(ALI) and the acute respiratory distress syndrome (ARDS) in infants, children, and adults …

Exogenous surfactant administration is currently being tested in patients with the acute
respiratory distress syndrome (ARDS). The results of the studies have varied because …

Exogenous surfactants have been used as an effective treatment of neonatal respiratory
distress syndrome (RDS). Different preparations of surfactant carry different biophysical and …

The efficacy of surfactant replacement therapy for pediatric and adult lung injuries has been
an ongoing area of investigation for more than 25 years. Surfactant therapy is lifesaving in …

Surfactant treatment is standard of care for infants who have respiratory distress syndrome
(RDS). However, many practical questions remain about what RDS is, and who should be …